Enovix Announces New Chief Financial Officer (RSVA)
- Dow hits milestone, S&P breaks record high on tech rally
- Thermo Fisher Scientific (TMO) to Acquire PPD, Inc. (PPD) for $47.50/sh, $17.4 Billion
- U.S. retail sales post largest gain in 10 months; weekly jobless claims fall
- Dell (DELL) Gains on Spin-Off of its 81% Stake in VMware (VMW), Analysts Bulled-Up as It Could Unlock $20 Per Share of Value for DELL
- The Stock Market is Almost 'Completely Broken' - Einhorn
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Enovix Corporation, the leader in the design and manufacture of next generation 3D Silicon™ Lithium-ion batteries, today announced the appointment of Steffen Pietzke as Chief Financial Officer, effective immediately. In his role, Pietzke will lead the finance organization as Enovix prepares to become a publicly listed company. The company's merger with Rodgers Silicon Valley Acquisition Corp (Nasdaq: RSVA, RSVAU, RSVAW), which was announced in February 2021, is expected to close in the second quarter of 2021. Additionally, Pietzke will build out and oversee financial operations and planning to support the company's battery production and growth plans.
"Steffen has decades of knowledge and experience guiding companies through major financial events -- his experience is exactly what Enovix needs as we transition from a privately-held to a publicly-traded company," said Harrold Rust, Enovix CEO and co-founder. "His expertise and leadership will be an incredibly valuable asset to our leadership team."
Pietzke brings more than 20 years of experience guiding public and private technology, life science and transportation companies across the U.S., Europe and Asia. Prior to Enovix, Pietzke was Vice President, Finance and Chief Accounting Officer at ALX Oncology Holdings Inc., where he managed all facets of corporate accounting and finance. Prior to ALX Oncology, Pietzke was Senior Vice President, Finance and Chief Accounting Officer at Tricida, Inc. Among his accomplishments, Pietzke has successfully managed finance organizations during two initial public offerings — ALX Oncology's $186 million IPO in 2020 and Tricida's $256 million IPO in 2018. He spent the first fifteen years of his career at Ernst & Young LLP and PricewaterhouseCoopers.
"The Enovix vision to support the advancement of mobile devices and electric vehicles through its next-generation batteries is what drew me to the company. Many startups have tried to develop breakthrough batteries, but few have made it as far as Enovix, which is poised to ramp commercial production at scale," said Pietzke. "I'm excited to join Enovix and lead the finance organization at such a pivotal moment for the company. My expertise in establishing public company infrastructure will support Enovix's long term growth as a commercial organization."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Veracyte (VCYT) Announces Retirement of CFO and Preliminary Q1 Results
- Western Alliance Bancorporation (WAL) Tops Q1 EPS by 43c
- Precision BioSciences (DTIL) Appoints Alan List, M.D. as Chief Medical Officer
Create E-mail Alert Related CategoriesCorporate News, Management Changes
Related EntitiesDefinitive Agreement, IPO, SPAC
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!